For the year ending 2025-12-31, SLS has $78,345K in assets. $7,474K in debts. $71,793K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 71,793 | |||
| Restricted cash and cash equivalents | 100 | |||
| Prepaid expenses and other current assets | 3,318 | |||
| Total current assets | 75,211 | |||
| Operating lease right-of-use assets | 963 | |||
| Goodwill | 1,914 | |||
| Deposits and other assets | 257 | |||
| Total assets | 78,345 | |||
| Accounts payable | 2,948 | |||
| Accrued expenses and other current liabilities | 3,525 | |||
| Operating lease liabilities | 544 | |||
| Total current liabilities | 7,017 | |||
| Operating lease liabilities, non-current | 457 | |||
| Total liabilities | 7,474 | |||
| Common stock, 0.0001par value 350,000,000shares authorized, 153,103,459 and 73,977,459shares issued and outstanding at december31, 2025 and 2024, respectively | 15 | |||
| Additional paid-in capital | 345,844 | |||
| Accumulated deficit | -274,988 | |||
| Total stockholders equity | 70,871 | |||
| Total liabilities and stockholders equity | 78,345 | |||
SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. (SLS)